Natera, Inc. (NTRA)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-market:
Loading interactive chart…
- Business Wire
New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer
AUSTIN, Texas, May 03, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced a new publication in JCO Precision Oncology reporting on the ability of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to detect recurrence early in patients with early-stage breast cancer. The full study can be found here.
- GuruFocus.com
Insider Sale: CFO Michael Brophy Sells Shares of Natera Inc (NTRA)
On April 29, 2024, Michael Brophy, the Chief Financial Officer of Natera Inc (NASDAQ:NTRA), sold 1,238 shares of the company.
- GuruFocus.com
Insider Sale: CEO and President Steven Chapman Sells Shares of Natera Inc (NTRA)
On April 29, 2024, Steven Chapman, CEO and President of Natera Inc (NASDAQ:NTRA), sold 4,084 shares of the company.
© 2024 Yahoo. All rights reserved.